Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexucabtagene Autoleucel Plus Dasatinib in ALL
NCT05993949Phase 1Active, not recruiting
- Sponsor
- Stanford University
- Start
- Oct 2023
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by Stanford University. Primary endpoint: Feasibility of dasatinib pulses at 1 month. Started Oct 2023; status: active, not recruiting.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05993949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05993949.